In prostate cancer, SPON2 has been reported as a diagnostic biomarker that offers advances over prostate specific antigen (PSA) with improvement of diagnostic sensitivity and specificity even in cohorts with NP levels of PSA, potentially lowering false negative tests and unnecessary biopsy (18). Here, SPON2 is linked to prostate carcinoma.